HAMILTON, Bermuda, Aug. 15 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) announced today that it has received a Paragraph IV Certification Notice from Barr Laboratories, Inc. ("Barr") advising the Company of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of FEMCON FE.
FEMCON FE, which was introduced by the Company during the second half of 2006, is a chewable oral contraceptive and is protected by U.S. Patent No. 6,667,050 which expires in 2019.
The Company is currently reviewing the detail of the Paragraph IV Certification Notice from Barr and continues to have full confidence in its intellectual property protecting FEMCON FE.
About Warner Chilcott
Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the United States. WCRX-G
Read more on http://www.warnerchilcott.com.
Warner Chilcott's Forward Looking Statements:
This press release contains forward-looking statements, including
statements concerning our product development efforts. These statements
constitute forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. The words "may," "might," "will," "should," "estimate," "project,"
"plan," "anticipate," "expect," intend," "outlook," "believe" and other
similar expressions are intended to identify forward-looking statements.
Readers are cautioned not to place undue reliance on these forward looking
statements, which speak only as of thei
|SOURCE Warner Chilcott Limited|
Copyright©2007 PR Newswire.